| Background: Angiogenesis and neovascularization have been considered to be related to the growth, dissemination and infiltration of malignant tumors. Vascular endothelial growth factor (VEGF) is the most important growth factor in the proliferation of the endothelial cells. Leukemia cells not only express and secret VEGF, which causes the vascular endothelial cells to roliferate and secret hematopioetin, but also express VEGF receptors in their membranes. Under the irritation of VEGF, leukemia cells proliferate faster and lose apoptosis partly. Tumor supplied group of factors(TSGF) consists of glucide, amino acid and other factors related to some kinds of tumor. It is one of the internationally accepted tumor markers, and a significant increase of TSGF level was found in the serum of early cancer. TSGF is widely acknowledged to be of great value in the assistant diagnosis of early cancer, and it has high sensitivity, specificity as a perfect new index for assistant diagnosis of wide-spectrum early cancer. Objective To determine the serum levels of VEGF and TSGF in patients with AL and to study the relationship between the levels of VEGF and TSGF and the occurrence, progression and prognosis of AL.Methods 55 patients with AL were chosen, including 31 cases of acute lymphocyte leukemia (ALL), 24 cases of acute myelogenous leukemia(AML). Serum levels of VEGF were measured by enzyme-linked immunosorbent assay(ELISA), Serum levels of TSGF were measured by colorimetric estimation and some other related items were determined as well. To compare the variation of VEGF and TSGF levels of AL patients pretreated and post-treated and to observe the correlation of VEGF, TSGF and other related items. All data were analyzed by SPSS 10.0.Results 1.Comparison of serum VEGF and TSGF between ALL, AML and normal subjects: (1). Serum VEGF levels of ALL, AML were ( 251.3±47.7) pg/ml, ( 271.7±64.4 ) pg/ml ,they were higher obviously than those "127.4±55.2pg/ml" of normal subjects and the difference was significant(t=6.71,6.18, P<0.001);serum TSGF levels of ALL, AML were (79.07±15.38)U/ml, (76.77±14.87) U/ml, they were higherobviously than those (51.29±7.54) U/ml of normal subjects and the difference was significant(t=6.847,5.009, P<0.01).2. AL were divided into completely remission(CR) group and no completely remission(NR) depended on the reaction on first chemical therapy. In AML patients, Serum VEGF levels of CR group pretreated were (251.3±58.7) pg/ml", and those of NR group were ( 307.5±66.5 ) pg/ml, and the difference between them was significant(t=2.36, P<0.05);In AML patients, Serum TSGF levels of CR group pretreated were (71.90±l 3.65) U/ml, and those of NR group were (89.74±16.58) U/ml, serum TSGF levels of NR group were higher obviously than those of CR group(t=2.13, P<0.05).3. Positive correlation were shown between serum VEGF and TSGF(r=0.5263, P<0.01). Conclusion (1). Serum VEGF and TSGF levels in patients with ALL and AML are higher than those of normal subjects. (2). Serum VEGF and TSGF are useful items for detecting the effect of treatment in ALL and AML. (3). Serum TSGF is a valuable item for evaluation prognosis in both ALL and AML, while significance of VEGF for evaluation prognosis is shown in AL. (4). Positive correlation is shown between serum VEGF and TSGF in AL. |
PDF Full Text Request